CEA cell adhesion molecule pseudogene 9Genealiases: CEACAM30P · CGM16
Q-omics provides the consensus-scored CEACAMP9 profile across patient tissues and cancer cell-line models. CEACAMP9 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CEACAMP9 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, CEACAMP9 RNA expression shows 5,089 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, HNSC, and TGCT as cancer lineages where CEACAMP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP9 survival associations across molecular data types. CEACAMP9 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP9 RNA expression–survival associations across cancer types. High CEACAMP9 expression shows unfavorable associations in MESO, KIRC, BRCA, HNSC and LIHC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for CEACAMP9 RNA expression.
This table summarizes CEACAMP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP9 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher CEACAMP9 RNA expression in tumor versus normal tissue (log2 FC = +0.048, t-test p = .013).
This table shows molecular features associated with CEACAMP9 in patient tissues and cancer cell lines. In patient samples, CEACAMP9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
